Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-term open-label extension study of lucerastat in adults with Fabry disease
NL-OMON55750Phase 3Active, not recruiting
- Sponsor
- Idorsia
- Start
- Jan 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of lucerastat in Fabry disease (FD), sponsored by Idorsia. Primary endpoints: Treatment-emergent adverse events and serious adverse events, Adverse events leading to premature discontinuation and 10 more. Started Jan 2020; status: active, not recruiting.
02
Drugs
lucerastat
03
Conditions
Fabry disease (FD)
Beyond the preview
Go deeper on NL-OMON55750.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON55750.